CORRESP 1 filename1.htm

 

 

October 19, 2022

 

VIA EDGAR

 

Securities and Exchange Commission

100 F Street N.E.

Washington, D.C. 20549-7010

USA

 

Re: Aptose Biosciences Inc.
  Registration Statement on Form S-3
  Filed October 11, 2022
  File No. 333- 267801

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aptose Biosciences Inc. (the “Company”) hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement (the “Registration Statement”) to October 21, 2022 at 5:00 p.m. (Eastern) or as soon thereafter as is practicable.

 

The Company also requests the Commission confirm the effective date and time of the Registration Statement in writing.

 

  APTOSE BIOSCIENCES INC.
     
  By: /s/ Fletcher Payne  
  Name: Fletcher Payne  
  Title Senior Vice President & Chief Financial Officer